Multiple Myeloma Coverage from Every Angle

Recent News

Daratumumab-Based Combination Therapy for Newly Diagnosed Multiple Myeloma
Phase I Trial Results With Immunotherapy bb21217 for Resistant Multiple Myeloma
Dana-Farber Receives $16.5 Million Gift to Support Multiple Myeloma Research
Combination Therapy for Frail and Unfit Patients Newly Diagnosed With Multiple Myeloma
Belantamab Mafodotin Granted Priority Review by FDA for Resistant Multiple Myeloma
Dual-Target CAR T-Cell Therapy in Resistant Multiple Myeloma
Venetoclax in Combination With Dexamethasone for Resistant Multiple Myeloma
Novel Monoclonal Antibody in Relapsed or Refractory Multiple Myeloma
Ixazomib-Based Combination for High-Risk Smoldering Multiple Myeloma
Is Ixazomib/Dexamethasone a New Option for Treating AL Amyloidosis?
ASH 2019: Dose-Finding Study of Novel Immunotherapy for Resistant Myeloma
ASH 2019: Early Trial Results With CAR T-Cell Therapy for Resistant Myeloma
ASH 2019: Characterizing Molecular Drivers of Myeloma Cells Via CRISPR Activation
ASH 2019: Addition of Selinexor to Treatment Regimen for Resistant Myeloma
ASH 2019: CANDOR Trial of Daratumumab Combination Therapy for Resistant Myeloma
ASH 2019: Early Results With Multiplexed Genetic Engineering in Treating Multiple Myeloma
STORM Trial: Oral Selinexor Combination in Refractory Myeloma
Carfilzomib-Based Therapy for Transplant-Eligible Patients With Myeloma
Transitioning From Bortezomib to Ixazomib in Multiple Myeloma
Daratumumab Plus Triplet Therapy for Transplant-Eligible Patients With Multiple Myeloma
Combination Therapy With Venetoclax in Resistant Multiple Myeloma
Early-Phase Trial of New Monoclonal Antibody Plus Pembrolizumab in Resistant Myeloma
Comparison of First-Line Treatments in Older Patients With Myeloma
Melflufen-Based Combination Therapy for Resistant Myeloma
Combination Therapy With Selinexor, Lenalidomide, and Dexamethasone in Resistant Myeloma
Orphan Drug Designation Granted to Immunotherapy for Multiple Myeloma
ESMO 2019: First-Line Versus Non–First-Line Bortezomib in Asian Patients With Myeloma
IMW 2019: Bortezomib-Based Regimens in Newly Diagnosed Multiple Myeloma
SOHO 2019: Are Real-World and Clinical Data Synchronized With Treatment of Resistant Myeloma?
Daratumumab Combination Approved for Transplant-Eligible Patients With Multiple Myeloma
SOHO 2019: Is Minimal Residual Disease Testing Ready for Prime Time?
IMW 2019: Daratumumab-Based Therapy Improves Response in Newly Diagnosed Myeloma
SOHO 2019: Update on the Future of Induction Therapy in Multiple Myeloma
Pilot Study of Ixazomib Plus Dexamethasone in High-Risk Smoldering Myeloma
Quality Care 2019: Program Hastens Start of Bone-Modifying Agents in Myeloma
Assessing Risk of Immunomodulatory Drug–Related Blood Clots in Patients With Multiple Myeloma

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.